Entheon Biomedical Corp. (CSE: ENBI), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of EBRX-101, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N,N-dimethyltryptamine (DMT)….

Entheon Biomedical Corp. (ENBI) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as well as nonclinical and clinical programs. US Provisional Patent Filed In furtherance of its…

Entheon Biomedical Corp. (CSE: ENBI) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.  Further to the Company’s…

As the psychedelic revolution becomes more socially accepted, academically acknowledged, and scientifically backed, many questions loom regarding the hierarchy of psychedelic substances.   The plethora of research, profusion of media coverage, and growing flood of anecdotes demonstrate that substances such as ayahuasca, DMT, psilocybin, MDMA, and LSD have groundbreaking healing potential. It has become evident that…